Longevity of the novel ConvaTec infusion set with Lantern technology
Open accessAbstract
Current insulin infusion sets are approved for only 2‐3 days. The novel ConvaTec infusion set with Lantern technology is designed to extend infusion set wear time. The goal of this pilot study was to evaluate the duration of wear for this set. This was a pilot safety study in adults with type 1 diabetes using tethered insulin pumps. Participants inserted the set and wore it for 10 days or until failure. Among 24 participants, two were excluded. Forty‐five per cent of the sets lasted 10 days. Median wear time was 9.1 (7.1, 10.0) days. Among 12 premature failures, six (50%) involved adhesive failures, four (33%) hyperglycaemia unresponsive to correction, one (8%) hyperglycaemia with ketones and one (8%) infection. Average CGM glucose per day of infusion set wear showed a statistically significant increase over time, while total daily insulin over the same period did not change. In this pilot study, the duration of wear for the novel infusion set exceeded previously reported commercial sets ( P < .001). This extended wear technology may eventually allow for a combined glucose sensor and infusion set.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A recent pilot study of 22 adults using varied insulin delivery systems demonstrated a survival rate of 82% at 6.8 days of wear during use of a novel IIS with multiple perforations within the cannula shaft, without significant change in glucose or daily insulin delivered at this time point.
“In addition to these findings, a recent pilot study of 22 adults (40.1 ± 14.3 years of age) using varied insulin delivery systems demonstrated a survival rate of 82% at 6.8 days of wear, during use of a novel IIS with multiple perforations within the cannula shaft (i.e., Lantern technology [ConvaTec, Inc., Deeside, United Kingdom]) without significant change in glucose or daily insulin delivered”
From Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial (2022) · cites this paper as [22]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredWithout recognition and replacement, IIS failures lead to inadequate insulin delivery, hyperglycemia, and increased risk for diabetes-related ketoacidosis (DKA).
“Without recognition and replacement, IIS failures lead to inadequate insulin delivery, hyperglycemia, and increased risk for diabetes-related ketoacidosis (DKA).2,5,8,9”
From Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community (2023) · cites this paper as [5]
Extended wear infusion sets present a wider timeframe for infusion failure.
“given the recent introduction of extended wear infusion sets, 32 which present a wider timeframe for infusion failure”
From Development of a Real-time Force-based Algorithm for Infusion Failure Detection (2024) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Schmid, V., Hohberg, C., Borchert, M., Forst, T., & Pfützner, A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400429 · Cited by 97 · see citing works
Randomized Trial of Infusion Set Function: Steel Versus Teflon
Patel, P. J., Benasi, K., Ferrari, G., Evans, M. G., Shanmugham, S., Wilson, D. M., & Buckingham, B. A. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0119 · Cited by 90 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 11
- [1]Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012; 6(4): 954– 964. 22920824 PMC3440169
- [2]Ziegler A, Williams T, Yarid N, Schultz DL, Bundock EA. Fatalities due to failure of continuous subcutaneous insulin infusion devices: a report of six cases. J Forensic Sci. 2019; 64(1): 275– 280. 29940703
- [3]Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care. 2001; 24(1): 69– 72. 11194244
- [4]Thethi TK, Rao A, Kawji H, Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications. 2010; 24(2): 73– 78. 19395280 PMC2854665
- [6]Karlin AW, Ly TT, Pyle L, Duration of infusion set survival in lipohypertrophy versus nonlipohypertrophied tissue in patients with type 1 diabetes. Diabetes Technol Ther. 2016; 18(7): 429– 435. 27227290 PMC4931738
- [7]Waldenmaier D, Zschornack E, Buhr A, Pleus S, Haug C, Freckmann G. A prospective study of insulin infusion set use for up to 7 days: early replacement reasons and impact on glycemic control. Diabetes Technol Ther. 2020; 22: 734– 741. 32167382
- [10]Denham D A head-to-head comparison study of the first-day performance of two factory-calibrated CGM systems. J Diabetes Sci Technol. 2020; 14(2): 493– 495. 31910661 PMC7196870
- [11]Norgaard K, Shin J, Welsh JB, Gjessing H. Performance and acceptability of a combined device for insulin infusion and glucose sensing in the home setting. J Diabetes Sci Technol. 2015; 9 (2): 215– 220. 25591857 PMC4604571
- [12]Rumpler M, Mader JK, Fischer JP, First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. Biosens Bioelectron. 2017; 88: 240– 248. 27554063
- [13]Tschaikner M, Simic A, Jungklaus M, Development of a singlesite device for conjoined glucose sensing and insulin delivery in Type-1 diabetes patients. IEEE Trans Biomed Eng. 2020; 67(1): 312– 322. 31144621
- [14]Tschaikner M, Powell K, Jungklaus M, Novel single-site device for conjoined glucose sensing and insulin infusion: performance evaluation in diabetes patients during home-use. IEEE Trans Biomed Eng. 2020; 67(1): 323– 332. 31251175
Cited by
Sorted by citations
Brazg, R., Garg, S. K., Bhargava, A., Thrasher, J. R., Latif, K., Bode, B. W., Bailey, T. S., Horowitz, B. S., Cavale, A., Kudva, Y. C., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0540 · Cited by 28 · see citing works
Self-citationHughes, M. S., Douvas, J. L., Layfield-Bryan, M., Blanco, L. E., Gray, J. C., Zapotoczny, G., Espinoza, J., Wilcox, J. H., & Lal, R. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0005 · Cited by 16 · see citing works
Self-citationDevelopment of a Real-time Force-based Algorithm for Infusion Failure Detection
Blanco, L. E., Wilcox, J. H., Hughes, M. S., & Lal, R. A. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241247530 · Cited by 2 · see citing works
Self-citation
- Authors
- Lal, R. A., Hsu, L., Zhang, J., Schøndorff, P. K., Heschel, M., & Buckingham, B.
- Affiliations
- Stanford Medicine (US)
- ConvaTec Copenhagen Denmark
- Corresponding author
- Lal, Rayhan A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-04-18
- Volume
- 23
- Issue
- 8
- Pages
- 1973-1977
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC8720264
- OpenAlex
- W3144920652
- Cited by
- 22
- References
- 2
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 13 · 2021: 3
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001085, UL1TR003142)
- National Institute of Diabetes and Digestive and Kidney Diseases (K12DK122550, DP3DK101055, DP3DK104059, K23DK122017, P30DK116074, T32DK007217)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Physical Sciences › Engineering › Biomedical Engineering › Intravenous Infusion Technology and Safety
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, adhesive failure, hyperglycemia, infection, continuous glucose monitoring, glucose sensor
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Pilot Projects, Technology, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
